ArticleMolecular pharmaceutics2014
Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- The Lysosome-Cathepsin Axis in Pancreatic Cancer: Mechanisms of Stromal Remodeling, Immune Evasion, and Therapy Resistance.Biomolecules · 2026Review
- Article
- Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy.Drug delivery · 2025Article
- Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer.Biomaterials · 2025Article
- Tailoring the Composition of HA/PEG Mixed Nano-Assemblies for Anticancer Drug Delivery.Molecules (Basel, Switzerland) · 2025Article
- Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy.Pharmaceutics · 2024Article
- Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.International journal of nanomedicine · 2024Article
- Improved Antitumor Efficiency ofInternational journal of nanomedicine · 2024Article
- PEGylated Strontium Sulfite Nanoparticles with Spontaneously Formed Surface-Embedded Protein Corona Restrict Off-Target Distribution and Accelerate Breast Tumour-Selective Delivery of siRNA.Journal of functional biomaterials · 2022Article
- Multimodal targeting of glioma with functionalized nanoparticles.Cancer cell international · 2022Review
- Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy.Asian journal of pharmaceutical sciences · 2022Review
- Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.International journal of nanomedicine · 2022Article
- Preliminary Study on the Therapeutic Effect of Doxorubicin-Loaded Targeting Nanoparticles on Glioma.Applied bionics and biomechanics · 2022Article
- Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.Cancers · 2021Review
- Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.Materials science & engineering. C, Materials for biological applications · 2020Article
- Intestinal OCTN2- and MCT1-targeted drug delivery to improve oral bioavailability.Asian journal of pharmaceutical sciences · 2020Review
- A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.Acta pharmacologica Sinica · 2019Article
- 3,5,4'-trimethoxy-trans-stilbene loaded PEG-PE micelles for the treatment of colon cancer.International journal of nanomedicine · 2019Article
- Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile.Drug delivery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gemcitabine is a potent anticancer drug approved for the treatment of pancreatic, non-small-cell lung, breast, and ovarian cancers. The major deficiencies of current gemcitabine therapy, however, are its rapid metabolic inactivation and narrow therapeutic window. Herein, we employed polyethylene glycol-b-distearoylphosphatidylethanolamine (PEG-DSPE)/tocopheryl polyethylene glycol 1000 succinate (TPGS) mixed micelles as a delivery system, to improve the pharmacokinetic characteristics of gemcitabine and enhance its antitumor efficacy. By conjugating stearic acid to gemcitabine and subsequently encapsulating stearoyl gemcitabine (GemC18) within PEG-DSPE/TPGS mixed micelles, the deamination of gemcitabine was delayed in vitro and in vivo. Importantly, compared to free gemcitabine, GemC18-loaded micelles pronouncedly prolonged the circulation time of gemcitabine and elevated its concentration in the tumor by 3-fold, resulting in superior antitumor efficacy in mice bearing human pancreatic cancer BxPC-3 xenografts. Our findings demonstrate the promise of PEG-DSPE/TPGS mixed micelles as a nanocarrier system for the delivery of gemcitabine to achieve safer and more efficacious therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.